Announcements Trials

Browse Landscape

Status

Completed 30 Recruiting 11 Terminated 5 Unknown 3 Active not recruiting 3 Suspended 1 Not yet recruiting 1 Available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Neoplasms 14 Carcinoma, Non-Small-Cell Lung 8 Sarcoma 6 Prostatic Neoplasms 6 Pancreatic Neoplasms 6 Neuroblastoma 6 Multiple Myeloma 6 Recurrence 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Melanoma 5 Ovarian Neoplasms 4 Leukemia, Myeloid, Acute 4 Glioblastoma 4 Breast Neoplasms 4 Stomach Neoplasms 3 Small Cell Lung Carcinoma 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma 3 Hematologic Neoplasms 3 Head and Neck Neoplasms 3 Urinary Bladder Neoplasms 2 Primary Myelofibrosis 2 Pheochromocytoma 2 Osteosarcoma 2 Non-Muscle Invasive Bladder Neoplasms 2 Neuroectodermal Tumors, Primitive 2 Neoplasm Metastasis 2 Myelodysplastic Syndromes 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, Non-Hodgkin 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Available × Neurofibromatoses × Clear all

NCT05028166 2026-05-08

Individual Patient Compassionate Use of Mirdametinib

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡